Clinical Scorecard: Evaluating Ultrasound as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Ultrasound (US) is emerging as a predictor of pathological response to neoadjuvant chemotherapy.
• The systematic review included 72 studies with a total of 8439 patients.
• Variability in study results highlights the need for standardized evaluation of US in this context.

Guideline-Based Recommendations

Diagnosis

• Utilize ultrasound imaging to assess response to neoadjuvant chemotherapy in breast cancer patients.

Management

• Incorporate ultrasound findings into treatment planning to personalize neoadjuvant chemotherapy.

Monitoring & Follow-up

• Regularly evaluate ultrasound results during the course of neoadjuvant chemotherapy.

Risks

• Consider potential biases in patient selection and diagnostic accuracy when interpreting ultrasound results.

Patient & Prescribing Data

Adult breast cancer patients undergoing neoadjuvant chemotherapy.

Ultrasound may help in predicting treatment response, thus guiding further management.

Clinical Best Practices

• Adhere to PRISMA guidelines for systematic reviews when evaluating ultrasound studies.
• Conduct thorough quality assessments of studies using QUADAS-2 to evaluate bias.

References

• Systematic Review and Meta-Analysis